Picard Medical, Inc. (PMI) presents a deeply negative liquidation recovery posture as of March 31, 2026. MFFAIS pre-computed cash liquidation value is -$11.7M and operating liquidation value is -$4.4M, consistent with the filing's own going-concern disclosure. The company has reported accumulated operating losses since inception, with a Q1 2026 net loss of $7.6M on revenues of only $1.15M. Under a liquidation lens, haircutted asset values are overwhelmed by face-value liabilities. Tangible assets are minimal: net PP&E of $184K (at 50-70% recovery, approximately $92-129K), operating lease ROU asset of $284K (zero recovery on wind-up given the lease is a liability mirror), and finance lease ROU of $141K (limited recovery on specialized office equipment). AR of approximately $735K (per customer concentration disclosures: Customer A $566K, Customer J $172K) recovers at 90-95%, yielding roughly $660-698K. Inventory and other current asset recovery is not separately quantifiable from the truncated TAG_CONTEXT, but given the specialized nature of FDA-regulated cardiac device inventory, 60% haircut recovery is likely optimistic. The liability stack is the primary driver of negative recovery. The $15M face-value Senior Secured Note issued December 2025 carries a first-priority lien on all tangible and intangible assets; as of March 31, 2026, its fair value was marked at $2.2M (company elected fair value option under ASC 825), but face value obligations remain $15M minus partial redemptions already settled in Q1 2026 (approximately $2.1M settled in shares). The note holder also holds 7.0M warrants classified as liabilities under ASC 815-40 with ratchet provisions. Operating lease liability (present value) is $329K, all current, expiring January 2027 with no renewal option. Finance lease liability totals $88K. A $0.7M related-party note from Fang Family Fund I (February 2026) bears 6% interest and a security interest in all assets, subordinated to the senior secured note. The putative securities class action filed February 2, 2026 (Louie v. PMI, NDCA) seeking unspecified damages represents an unquantified contingent liability not accrued. The NYSE noncompliance notice received May 8, 2026 (post-period) signals exchange listing risk and further constrains equity financing optionality. The SynCardia Beijing contingent investment commitment of $2.9M is not yet triggered and is not recognized on-balance-sheet. Material weaknesses in internal controls (lack of segregation of duties, inadequate multi-level review) are disclosed and unremediated. Compared to the prior filing (10-K for year ended December 31, 2025), the Q1 2026 period saw: (1) $2.1M of Senior Secured Note principal settled via share issuances, reducing the note's fair value from $5.4M to $2.2M but generating a $6.1M loss on settlement; (2) the operating lease ROU decreased from $363K to $284K as the lease runs to January 2027; (3) all Series A-1 Preferred Stock converted in July 2025, eliminating that liquidation preference claim. The filing does not separately tag any balance sheet XBRL items in the TAG_CONTEXT provided, preventing tag-level quantification; all balance sheet figures referenced here are sourced from narrative disclosures in the filing body. The MFFAIS CLV/LLV of -$11.7M and OLV of -$4.4M bracket the recovery range; equity recovery to common stockholders in a wind-up scenario is negative under any reasonable assumption.
▼ Community Notes